Dingyuan Biomedical Technology

Dingyuan Biotech is a clinical-stage biopharmaceutical company focused on developing innovative therapies for diseases driven by the complement system. The company utilizes a proprietary technology platform to engineer recombinant proteins that regulate complement activation pathways, targeting rare hematological, nephrological, and ophthalmic conditions. Its lead program, DY-001, is a first-in-class recombinant protein designed to treat paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated disorders. Dingyuan is also advancing a pipeline of candidates for geographic atrophy and other high-prevalence inflammatory diseases. The company is headquartered in Shanghai and is backed by prominent life science investors.